Analyzing Pacira Pharmaceuticals (PCRX) & Its Rivals
Pacira Pharmaceuticals (NASDAQ: PCRX) is one of 112 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Pacira Pharmaceuticals to similar businesses based on the strength of its risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.
This table compares Pacira Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pacira Pharmaceuticals Competitors||-3,613.35%||-52.28%||-8.30%|
This is a breakdown of recent ratings and target prices for Pacira Pharmaceuticals and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pacira Pharmaceuticals Competitors||944||3786||6004||164||2.49|
Pacira Pharmaceuticals presently has a consensus target price of $53.42, suggesting a potential upside of 48.79%. As a group, “Pharmaceuticals” companies have a potential upside of 27.43%. Given Pacira Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Pacira Pharmaceuticals is more favorable than its peers.
Institutional and Insider Ownership
44.2% of shares of all “Pharmaceuticals” companies are held by institutional investors. 6.6% of Pacira Pharmaceuticals shares are held by company insiders. Comparatively, 12.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Pacira Pharmaceuticals has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500. Comparatively, Pacira Pharmaceuticals’ peers have a beta of 0.86, meaning that their average stock price is 14% less volatile than the S&P 500.
Earnings and Valuation
This table compares Pacira Pharmaceuticals and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Pacira Pharmaceuticals||$281.47 million||-$34.94 million||-20.99|
|Pacira Pharmaceuticals Competitors||$7.88 billion||$2.51 billion||1.34|
Pacira Pharmaceuticals’ peers have higher revenue and earnings than Pacira Pharmaceuticals. Pacira Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.
Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.